BIOMARKERS OF DEPRESSION BEFORE AND DURING THE COVID ERA
Keywords:
depression, biomarkers, post-Covid depressionAbstract
As one of the most common diseases today, depression is of great social and economic importance. That is why enormous efforts are being made to shed light on its etiology and pathogenesis, which is still unknown. Thanks to the rapid technological development in recent years, there is an intensive development of neuroscience Neuroimaging technology and new sensitive laboratory tests allow the detection of active molecules involved in pathophysiological processes, and therefore can be considered potential biomarkers.
Although a biomarker specific for depression has not yet been isolated, a number of studies have confirmed changes in active substance levels in depressed patients compared to controls. In this text, we will look at potential biomarkers that are the focus of research: growth factors, ie. Brain derived neutrophic factor (BDNF), inflammatory and neuroendocrine biomarkers, indicators of oxidative and nitrosative stress, as well as neuroimaging markers that are intensively studied.
The COVID pandemic that has lasted for the last 2 years has completely changed humanity and led to unforeseeable health and economic consequences. The incidence of post-COVID depressive states has led to the study of potential biomarkers in many studies.
The possibility of insight into the biological basis of the depressive process, both in unipolar depression and post-Covid depressive states, would enable new achievements in the diagnosis, therapy and prognosis of this disorder and contribute to a better quality of life for patients and their families
References
Besedovsky, H.O., & Rey, A. (1996). Immune-neuro-endocrine interactions: facts and hypotheses, Endocr Rev; 17: 64–102.
Biomarkers Definition Working group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Ther.,69(3),89–95.
De Lorenzo, R., Conte, C., Lanzani, C., Benedetti, F., Roveri, L., & Mazza M.G. (2020). Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study., PLoS ONE 15, e0239570.
Dwivedi, Y., Rizavi, H.S., Conley, R.R., Roberts, R.C., Tamminga, C.A., & Pandey, G.N. (2003). Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in post-mortem brain of suicide subjects, Arch Gen Psychiatry, 60:804-815.
Jani, B.D., McLean, G., Nicholl, B.I., Barry, S.J.E., Sattar, N., Mair, F.S., & Cavanagh, J.(2015). Risk assessment and predicting outcomes in patient with depressive symptoms : A revew of potentional role of periferial blood based biomarkers, Front Hum Neurosci, 9: 18 .
Jusczuk, G. (2021). Chronic Stress and Oxidative Stress as Common Factors of the Pathogenesis of Depression and Alzheimer’s Disease: The Role of Antioxidants in Prevention and Treatment, Antioxidant
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J.M. (2002). Decreased serum brain- derived neurotrophic factor levels in major depressed patient, Psychiatry Research, 109, 143-148
Kong, X., Zheng, K., Tang, M., & Kong, F. (2020). Prevalence and Factors Associated withDepression and Anxiety of Hospitalized Patients with COVID-19., medRxiv
Lorkiewicz, P., & Waszkievicz N. (2021). Biomarkers of post -COVID Depresion , J.Clin.Med 10, 4142.
Mark, J., Niciu, M.J., Daniel, C., Mathews, D.C., Nugent, A.C., Ionescu, D.F., Furey, M.L., Richards, E.M., Machado-Vieira, R., & Zarate, J.C.A.(2014) .Developing biomarkers in mood disorders research through the use of rapid – acting antidepressants, Depression and Anxiety, 31, 297–307.
Mazza, M.G., De Lorenzo, R., & Conte, C. (2020). Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors, Brain Behav. Immun. , 89, 594–600.
Mossner, R., Mikova, O., Koutsilieri, E., Saoud, M., Ehlis, A.C., Muller, N., Fallgatter, A.J., & Riederer, P. (2007). Consensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression, The World Journal of Biological Psychiatry, 8(3), 141-174.
Miller, A.H., Maletic, V., & Raison, C.L. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry,65(9):732–741
Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., & Monteggia, L.M .(2002). Neurobiology of depression, Neuron,34: 13–25.
Niciu, M.J., Mathews, D.C., Nugent, A.C., Ionescu, D.F., Furey, M.L., & Richards, E.M. (2014). Developing Biomarkers in Mood Disoreders Research Through the Use of Rapid-Acting Antidepressants, Depress Anxiety, 31(4) : 297-307.
Perosa Carnel, B., & Sicada Rosha, N. (2021) Brain-derived neurotrophic factor (BDNF) and inflammatory markers: Perspectives for the management of depression, Progress in Neuro-Psychopharmacology and Biolological Psyhiatry 108 110-151
Shimizu, E., Hashimoto, K., & Okamura, N. (2003) . Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants, Biol Psychiatry,54:70–75.
Sen, S., Duman, R., & Sanacora, G. (2003). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications, Biol Psychiatry , 64, 527–532.
Smith, R.S. (1991). The macrophage theory of depression, Med Hypotheses 199, 35,298–306.
Schmidt, H.D., Shelton, R.C., & Duman, R.S. (2011). Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology, Neuropsychopharmacology, 36: 2375- 2394 .
Vasan, R.S. (2006). Biomarkers of cardiovascular disease: molecular basis and practical considerations, Circulation,113(19), 2335– 2362.
